Comparative efficacy of cephradine-loaded silver and gold nanoparticles against resistant human pathogens. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Khan, Ajmal; Jabeen, Humera; Ahmad, Touqeer; Rehman, Najeeb Ur; Khan, Saleha Suleman; Shareef, Huma; Sarwar, Rizwana; Yahya, Saira; Hussain, Nusrat; Uddin, Jalal; Hussain, Javid; Al-Harrasi, Ahmed
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 50:Issue 1(2022)
• Page Start: 312
• Page End: 321
• Publication Date: 2022-12-31
• Subjects: Cephradine -- nanoparticles -- TEM -- FTIR -- antibiofilm; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.1080/21691401.2022.2144340
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract: Infections caused by drug-resistant bacteria are major health concerns worldwide. We successfully synthesized cephradine gold nanoparticles (Ceph-Au NPs) and cephradine silver nanoparticles (Ceph-Ag NPs) and compared their efficacy against resistant human pathogens. X-Ray diffraction (XRD), Atomic Force Microscopy (AFM) and Transmission Electron Microscopy (TEM) results showed that average particle size of Ceph-Au NPs and Ceph-Ag NPs were 7 and 12 nm, respectively. Fourier Transform Infra-red spectroscopy (FTIR) spectra revealed the conjugation of –NH2 and –OH functional moieties with the nanoparticle (NP) surfaces. These NPs significantly inhibited the biofilm of Streptococcus mutans ( S. mutans) and methicillin-resistant Staphylococcus aureus (MRSA) in the range of 61.25–250 µg/mL. Ceph-Au NPs are more active than Ceph-Ag NPs and can be used to treat the diseases associated with MRSA and S. mutans.